OBJECTIVE： To observe the effectiveness and safety of liraglutide combined with insulin and glipizide in the treatment of subclinical hypothyroidism （SCH） complicated with type 2 diabetes in the elderly patients. METHODS： Totally 82 elderly patients with SCH complicated with type 2 diabetes were selected from our hospital during Dec. 2013-Dec. 2015， and then divided into trial group （40 cases） and control group （42 cases） according to random number table. Control group was given Insulin injection+Glipizide tablets. Trial group was additionally given Liraglutide injection 0.6 mg， sc， qd， on the basis of control group. Treatment courses of 2 groups lasted for 12 weeks. The levels of blood glucose [fasting glucose， postprandial 1 h and 2 h glucose， mean of daily differences （MODD）， mean amplitude of glycemic excursions （MAGE）]， glycosylated hemoglobin， body weight， total cholesterol， blood pressure [systolic blood pressure （SBP）， diastolic blood pressure （DBP）]， thyroid stimulating hormone （TSH） and homeostasis model assessment （HOMA-B） were observed in 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS： Totally 4 patients of control group withdrew from the study， and no one withdrew from the study in trial group. Before treatment， there was no statistical significance in the levels of blood glucose， glycosylated hemoglobin， body weight， total cholesterol， blood pressure， TSH and HOMA-B （P＞0.05）. After treatment， body weight and total cholesterol level of trial groups were significantly decreased and lower than those of control group， with statistical significance （P＜0.05）. The levels of blood glucose， glycosylated hemoglobin， blood pressure （SBP， DBP） and TSH in 2 groups were decreased significantly， while HOMA-B levels were increased significantly， and trial group was significantly better than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between trial group （12.5％） and control group （19.0％） （P＞0.05）. CONCLUSIONS： Liraglutide combined with insulin and glipizide for elderly patients with SCH complicated with type 2 diabetes can effectively reduce blood glucose level， keep blood glucose stable， control the increase of body weight and improve islet B cell function with good safety.